Verition Fund Management
ZNTL icon

Verition Fund Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Verition Fund Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-122,282
Closed -$194K – 3912
2025
Q1 		$194K Sell
122,282
-1,094,812
-90% -$2.36M ﹤0.01% 3058
2024
Q4 		$3.69M Sell
1,217,094
-287,226
-19% -$941K 0.01% 1115
2024
Q3 		$5.54M Buy
1,504,320
+951,500
+172% +$3.46M 0.03% 788
2024
Q2 		$2.26M Sell
552,820
-602,416
-52% -$6.73M 0.01% 1195
2024
Q1 		$18.2M Buy
1,155,236
+810,619
+235% +$11.1M 0.12% 141
2023
Q4 		$5.22M Sell
344,617
-192,742
-36% -$2.81M 0.04% 431
2023
Q3 		$10.8M Buy
537,359
+30,339
+6% +$770K 0.13% 191
2023
Q2 		$14.3M Buy
507,020
+116,438
+30% +$2.79M 0.19% 130
2023
Q1 		$6.72M Buy
+390,582
New +$7.91M 0.09% 285
2022
Q2 		– Sell
-40,714
Closed -$1.88M – 3163
2022
Q1 		$1.88M Buy
+40,714
New +$2.2M 0.02% 1017
2021
Q2 		– Sell
-64,718
Closed -$2.81M – 2184
2021
Q1 		$2.81M Buy
64,718
+53,148
+459% +$2.29M 0.03% 331
2020
Q4 		$601K Sell
11,570
-7,830
-40% -$353K 0.01% 620
2020
Q3 		$634K Buy
+19,400
New +$679K 0.01% 490

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Verition Fund Management's ZNTL Position: Q2 2025 in Review

Verition Fund Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 122,282 shares — an estimated $194K sold.

Verition Fund Management first reported a position in ZNTL in Q3 2020 and held it in 13 quarters. The position peaked at $18.2M in Q1 2024. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Verition Fund Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 122,282 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $194K.
  • Verition Fund Management first reported a position in Zentalis Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Verition Fund Management's Zentalis Pharmaceuticals position peaked at $18.2M in Q1 2024.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.